Cite

HARVARD Citation

    Byun, J. et al. (2022). A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert opinion on pharmacotherapy. pp. 1247-1257. [Online]. 
  
Back to record